FP-025

Foresee Pharmaceuticals has dosed the first patient in its Phase 2 WINDWARD study evaluating mirivadelgat, a first-in-class oral ALDH2 activator, for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Independent Data Safety Monitoring Board issues third positive recommendation for Foresee Pharmaceuticals' Phase 3 Casppian study of leuprolide (FP-001) in central precocious puberty, with trial at 75% enrollment.

The FDA has set August 29, 2025, as the PDUFA goal date for Foresee Pharmaceuticals' 3-month formulation of CAMCEVI (leuprolide mesylate) for advanced prostate cancer.

Foresee Pharmaceuticals has submitted an NDA to the FDA for a 3-month depot formulation of leuprolide mesylate (Camcevi) to treat advanced prostate cancer.

Foresee Pharmaceuticals' linvemastat (FP-020), a novel oral MMP-12 inhibitor, demonstrates a favorable safety and tolerability profile in a Phase 1 clinical trial.